A rationally designed bipyridine ligand and a non-nucleophilic guanidine additive enable visible-light-driven nickel ...
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is building a business model that differs from that of many drug developers ...
Ligand Pharmaceuticals has delivered a very strong run in recent years, and the question now is whether the cash the business ...
Pharmaceutical & Biotech Stock Introductory Series, Part 2, Episode 1 / 12 Episodes Total]IntroductionLigand Pharmaceuticals ...
Radicals, atoms or molecules that readily react with other substances to form new bonds, are useful tools for building complex substances such as pharmaceuticals. But even when a radical is generated ...
Ligand Pharmaceuticals Incorporated is currently listed on NASDAQ under LGND. One share of LGND stock can currently be purchased for approximately $293.26. Is Ligand Pharmaceuticals Incorporated (LGND ...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a ...
As per the terms of the deal, Ligand has committed up to $41 million in exchange for a mid-single-digit to low double-digit royalty on worldwide annual net sales of all current and future AvenCell ...
Andrew Reardon's October 2 Stock Option Exercise and Multiple Share Sales at Ligand Pharmaceuticals As disclosed in the Form ...
Shares of Ligand Pharmaceuticals (LGND) are absolutely flying, up more than 92% this year, as investors line up behind the company's unique royalty-based business model. Ligand Pharma is a biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results